Price (delayed)
$33.25
Market cap
$2.22B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.63
Enterprise value
$2.13B
Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate,
There are no recent dividends present for CRNX.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.